Novel approaches to glioma drug design and drug screening

Trimodal Glioblastoma Treatment Consisting of Concurrent Radiotherapy, Temozolomide, and the Novel TGF-β Receptor I Kinase Inhibitor LY2109761

(2015) Mengxian Zhang et al.   NEOPLASIA

The Brain Microenvironment Preferentially Enhances the Radioresistance of CD133+ Glioblastoma Stem-like Cells

(2015) Muhammad Jamal et al.   NEOPLASIA

Modeling Adult Gliomas Using RCAS/t-va Technology

(2014) Dolores Hambardzumyan et al.   Translational Oncology

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

(2013) Jakob Lovén et al.   CELL

Screening of anti-cancer agent using zebrafish: Comparison with the MTT assay

(2012) Yigen Li et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

New substituted 4H-chromenes as anticancer agents

(2012) Shivaputra A. Patil et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

53BP1 Is a Haploinsufficient Tumor Suppressor and Protects Cells from Radiation Response in Glioma

(2012) M. Squatrito et al.   CANCER RESEARCH

Stem-like Tumor-Initiating Cells Isolated from IL13R 2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine-Redirected T Cells

(2012) C. E. Brown et al.   CLINICAL CANCER RESEARCH

Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951

(2012) Lale Erdem-Eraslan et al.   JOURNAL OF CLINICAL ONCOLOGY

Design and in Vitro Activities of N-Alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, Novel, Small-Molecule Hypoxia Inducible Factor-1 Pathway Inhibitors and Anticancer Agents

(2012) Jiyoung Mun et al.   JOURNAL OF MEDICINAL CHEMISTRY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009

(2012) T. A. Dolecek et al.   NEURO-ONCOLOGY

Drug Resistance in Glioblastoma: A Mini Review

(2012) Catherine P. Haar et al.   NEUROCHEMICAL RESEARCH

Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma

(2012) B. D. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting Glioma Stem Cells by Functional Inhibition of a Prosurvival OncomiR-138 in Malignant Gliomas

(2012) Xin Hui Derryn Chan et al.   Cell Reports

8-Hydroxynaphthalene-1,4-dione derivative as novel compound for glioma treatment

(2011) Giuseppe Zagotto et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The Central Nervous System-Restricted Transcription Factor Olig2 Opposes p53 Responses to Genotoxic Damage in Neural Progenitors and Malignant Glioma

(2011) Shwetal Mehta et al.   CANCER CELL

Cooperativity within and among Pten, p53, and Rb Pathways Induces High-Grade Astrocytoma in Adult Brain

(2011) Lionel M.L. Chow et al.   CANCER CELL

The origins of glioma: E Pluribus Unum?

(2011) F. A. Siebzehnrubl et al.   GLIA

Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) Inhibitor 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): A Novel Oncology Therapeutic Agent

(2011) Robert L. Hudkins et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery

(2011) Mark R. Gilbert et al.   JOURNAL OF NEURO-ONCOLOGY

Impact of high-throughput screening in biomedical research

(2011) Ricardo Macarron et al.   NATURE REVIEWS DRUG DISCOVERY

Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases

(2011) T Papagiannakopoulos et al.   ONCOGENE

Glioblastoma Models Reveal the Connection between Adult Glial Progenitors and the Proneural Phenotype

(2011) Liang Lei et al.   PLoS One

Thiopurine Methyltransferase Predicts the Extent of Cytotoxicty and DNA Damage in Astroglial Cells after Thioguanine Exposure

(2011) Amira Hosni-Ahmed et al.   PLoS One

Treatment Resistance Mechanisms of Malignant Glioma Tumor Stem Cells

(2011) Philip Schmalz et al.   Cancers

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies

(2010) N. A. de Vries et al.   CLINICAL CANCER RESEARCH

Design and synthesis of novel 3,4-disubstituted pyrazoles for nanomedicine applications against malignant gliomas

(2010) Mauro Comes Franchini et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Synthesis and evaluation of new 1,2,3,4-tetrahydroisoquinoline analogs as antiglioma agents

(2010) Renukadevi Patil et al.   MEDICINAL CHEMISTRY RESEARCH

Designer Therapies for Glioblastoma Multiforme

(2009) Sith Sathornsumetee et al.   Annals of the New York Academy of Sciences

Identification of novel autophagy regulators by a luciferase-based assay for the kinetics of autophagic flux

(2009) Thomas Farkas et al.   Autophagy

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

(2009) D A Reardon et al.   BRITISH JOURNAL OF CANCER

Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma

(2009) Jennifer A. Quinn et al.   CANCER

Malignant Astrocytomas Originate from Neural Stem/Progenitor Cells in a Somatic Tumor Suppressor Mouse Model

(2009) Sheila Alcantara Llaguno et al.   CANCER CELL

Identification of Compounds Selectively Killing Multidrug-Resistant Cancer Cells

(2009) D. Turk et al.   CANCER RESEARCH

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy

(2009) Jennifer A. Quinn et al.   JOURNAL OF NEURO-ONCOLOGY

Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience

(2009) P. L. Nghiemphu et al.   NEUROLOGY

Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis

(2009) Haihao Zhu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Chemotherapy for Malignant Gliomas

(2009) Teri N. Kreisl   SEMINARS IN RADIATION ONCOLOGY

Antiglioma action of xanthones from Gentiana kochiana: Mechanistic and structure–activity requirements

(2008) Aleksandra Isakovic et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives

(2008) Malcolm W.B. McCulloch et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Cannabinoids for Cancer Treatment: Progress and Promise

(2008) S. Sarfaraz et al.   CANCER RESEARCH

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan

(2008) R. M. Zuniga et al.   JOURNAL OF NEURO-ONCOLOGY

Current issues in ER and HER2 testing by IHC in breast cancer

(2008) Allen M Gown   MODERN PATHOLOGY

Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization

(2008) A. Claes et al.   MOLECULAR CANCER THERAPEUTICS

p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation

(2008) Hongwu Zheng et al.   NATURE

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

High-throughput kinase profiling as a platform for drug discovery

(2008) David M. Goldstein et al.   NATURE REVIEWS DRUG DISCOVERY

Experience with irinotecan for the treatment of malignant glioma

(2008) James J. Vredenburgh et al.   NEURO-ONCOLOGY

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

(2008) Gaspar J. Kitange et al.   NEURO-ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY